89bio, inc. announces upsized pricing of $94.5 million public offering of common stock, pre-funded warrants and warrants

San francisco, june 29, 2022 (globe newswire) -- 89bio, inc. (“89bio”) (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 18,675,466 shares of its common stock and accompanying warrants to purchase up to 9,337,733 shares of common stock at a combined public offering price of $3.55 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,944,252 shares of its common stock and accompanying warrants to purchase up to 3,972,126 shares of common stock at a combined public offering price of $3.549. the pre-funded warrants have an exercise price of $0.001 per share, and are exercisable immediately. the warrants have an exercise price of $5.325 per share, are exercisable immediately, and will expire two years following the date of issuance. the gross proceeds of the offering to 89bio, before deducting the underwriting discounts and commissions and other offering expenses payable by 89bio, are expected to be approximately $94.5 million. the offering is expected to close on or about july 1, 2022, subject to the satisfaction of customary closing conditions.
ETNB Ratings Summary
ETNB Quant Ranking